APTITUDE HEALTH®

EPICS

EPICS: Multiple Myeloma in 2021 and Beyond

September 17–18, 2021

FULL REPORT

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
September 17–18, 2021

DISEASE STATE AND DATA PRESENTATIONS
by key experts

INSIGHTS REPORT
including postmeeting analyses and actionable recommendations

PANEL: Key experts in multiple myeloma
> 10 from US
> 1 from Canada

MULTIPLE MYELOMA-SPECIFIC DISCUSSIONS
on latest research updates, therapeutic advances, and their application in clinical decision-making

Panel Consisting of 10 US and 1 Canadian Multiple Myeloma Experts

EPICS



APTITUDE HEALTH

Meeting Agenda (Day 1 – September 17, 2021)

EPICS

Time	Topic	Speaker/Moderator
9.00 AM – 9.10 AM (10 min)	Welcome and Introductions	Rafael Fonseca, MD
9.10 AM – 9.30 AM (20 min)	Pursuing the Cure for Myeloma	Keith Stewart, MB, ChB
9.30 AM – 10.00 AM (30 min)	Discussion – Pursuing the Cure for Myeloma	Moderator: Rafael Fonseca, MD
10.00 AM – 10.15 AM (15 min)	Immunomodulatory Agents – With Us Since 1999	Sagar Lonial, MD
10.15 AM – 10.50 AM (35 min)	Discussion – Immunomodulatory Agents – With Us Since 1999	Moderator: Rafael Fonseca, MD
10.50 AM – 11.00 AM (10 min)	BREAK	
11.00 AM – 11.15 AM (15 min)	The Evolving Role of Proteasome Inhibitors (PIs)	Irene Ghobrial, MD
11.15 AM – 11.50 AM (35 min)	Discussion – The Evolving Role of Proteasome Inhibitors (PIs)	Moderator: Rafael Fonseca, MD
11.50 AM – 12.10 PM (20 min)	Summary Discussion: Key Takeaways on Multiple Myeloma	Rafael Fonseca, MD
12.10 PM – 12.20 PM (10 min)	Wrap-up and Overview	Rafael Fonseca, MD

Meeting Agenda (Day 2 – September 18, 2021)

EPICS

Time	Topic	Speaker/Moderator
9.00 AM – 9.05 AM (5 min)	Agenda Review	Rafael Fonseca, MD
9.05 AM – 9.20 AM (15 min)	Monoclonal Anti-CD38	Thomas Martin, MD
9.20 AM – 10.00 AM (40 min)	Discussion – Monoclonal Anti-CD38	Moderator: Rafael Fonseca, MD
10.00 AM – 10.15 AM (15 min)	CAR T Therapies for the Treatment of MM	Peter Voorhees, MD
10.15 AM – 10.45 AM (30 min)	Discussion – CAR T Therapies for the Treatment of MM	Moderator: Rafael Fonseca, MD
10.45 AM – 11.00 AM (15 min)	Bispecific Agents for the Treatment of MM	Craig Hofmeister, MD, MPH
11.00 AM – 11.20 AM (20 min)	Discussion – Bispecific Agents for the Treatment of MM	Moderator: Rafael Fonseca, MD
11.20 AM – 11.30 AM (10 min)	BREAK	
11.30 AM – 11.40 AM (10 min)	Other Agents on the Horizon in MM and Moving the Needle Forward	Leif Bergsagel, MD, FASCO
11.40 AM – 12.10 PM (30 min)	Discussion – Other Agents on the Horizon in MM and Moving the Needle Forward	Moderator: Rafael Fonseca, MD
12.10 PM – 12.30 PM (20 min)	Summary Discussion: Key Takeaways on Multiple Myeloma	Rafael Fonseca, MD
12.30 PM – 12.40 PM (10 min)	Wrap-up and Overview	Rafael Fonseca, MD

APTITUDE HEALTH®

EPICS

Updates in Multiple Myeloma

Pursuing the Cure for Myeloma

Presented by Keith Stewart, MB, ChB

EPICS

Goals of therapy and the role of cytogenetic abnormalities

High-risk patients continue to do worse than







APTITUDE HEALTH

Key Insights: Pursuing the Cure for Myeloma

EPICS

Goals of therapy

Experts are uncertain if multiple myeloma (MM) is a curable disease, as

Role of cytogenetic abnormalities

Risk stratification of patients remains important, but

[redacted]

[redacted]

Immunomodulatory Agents – With Us Since 1999

Presented by Sagar Lonial, MD

EPICS

IMiDs and potential impact of CELMoDs on SOC

IMiDs and dexamethasone are the central core for

Key Insights: Immunomodulatory Agents – With Us Since 1999

EPICS

IMiDs

Immunomodulatory drugs (IMiDs) remain a pivotal

CELMoDs and potential impact on SOC

Experts are excited for the availability of novel cereblon E3 ligase

The Evolving Role of Proteasome Inhibitors (PIs)

Presented by Irene Ghobrial, MD

EPICS

Frontline and maintenance therapy

Current data support the use of PIs in addition to Rd +

Key Insights: The Evolving Role of Proteasome Inhibitors (PIs)

EPICS

Frontline therapy

Experts are divided on the role of frontline

Maintenance therapy

Due to recently released data on mortality rates from the TOURMALINE trials,

Monoclonal Anti-CD38

Presented by Thomas Martin, MD

EPICS

Frontline and relapsed/refractory setting

Current trial data demonstrates that the addition of

IKEMA
Study design: Isa-Kd vs Kd in relapsed multiple myeloma

Kd+ CD38 combos



Key Insights: Monoclonal Anti-CD38

EPICS

Frontline setting

Most experts have adopted regimens that include a monoclonal anti-

Relapsed/refractory setting

Anti-CD38 antibody regimens are the preferred

CAR T Therapies for the Treatment of MM

Presented by Peter Voorhees, MD

EPICS

CAR Ts

BCMA-targeted CAR T-cell therapy in R/RMM is active

Idecabtagene Vicleucel: The KarMMa-2 Trial

Key Insights: CAR T Therapies for the Treatment of MM

EPICS

CAR Ts

CAR Ts are exciting options in MM, but more investigation is needed to improve on them and move them to earlier lines of therapy

Bispecific Agents for the Treatment of MM

Presented by Craig Hofmeister, MD, MPH

EPICS

Bispecific agents

Bispecifics are only just coming of age for MM



Key Insights: Bispecific Agents for the Treatment of MM

EPICS

Bispecific agents

While bispecific agents have shown promising results, experts called for further data to inform sequencing of the agents in relation to

Other Agents on the Horizon in MM and Moving the Needle Forward

Presented by Leif Bergsagel, MD, FASCO

EPICS

Other novel agents

Progress will not come just with novel therapies, but also

PFS Benefit in the Melflufen Arm Mainly Driven by Patients



Key Insights: Other Agents on the Horizon in MM and Moving the Needle Forward

EPICS

Other novel agents

Venetoclax is a promising treatment option for patients with t(11;14), and some experts called it a “game changer”